At GoBroad Healthcare Group (GHG), we are committed to advancing medical technology and pioneering new treatments for patients with complex diseases. As a research-driven hospital, we continuously strive to push the boundaries of clinical innovation. Our dedication to precision medicine, clinical research, and biomedical advancements has positioned us as a top oncology hospital, offering hope and cutting-edge therapies to patients nationwide.

We firmly believe that medical progress should serve patient needs first. Our hospital not only provides state-of-the-art diagnostic and treatment options but also actively engages in clinical research to accelerate the development of next-generation therapies. With an unwavering focus on improving patient outcomes, we are redefining excellence in oncology care.

Leading the Way in Nuclear Medicine Applications

One of our recent milestones in oncology treatment is the successful approval to conduct Lutetium-177 (Lu-177) radiopharmaceutical clinical applications. This achievement marks a significant step in advancing nuclear medicine in China, an area that has long been subject to strict regulatory oversight and complex approval processes. Our qualification in this field strengthens our position as a top oncology hospital and underscores our commitment to innovative treatment solutions.

The approval of Lu-177 nuclear therapy is particularly promising for patients with gastrointestinal and pancreatic neuroendocrine tumors. Under the leadership of Professor Lu Ming, a distinguished expert from Peking University Cancer Hospital and GoBroad Healthcare Group, we are currently conducting clinical trials on Peptide Receptor Radionuclide Therapy (PRRT) using Lu-177 for neuroendocrine tumors. This therapy has shown exceptional efficacy, significantly extending disease control duration compared to existing treatment options. Professor Lu Ming expresses great confidence in its potential, emphasizing the groundbreaking clinical value of radiopharmaceuticals in oncology treatment.

A Patient-Centered Approach to Oncology Care

At GoBroad, we recognize that a hospital is more than just a place for treatment—it is a source of hope and healing. Our reputation as a top oncology hospital is built not only on our medical advancements but also on our commitment to personalized patient care. We integrate a multidisciplinary approach, ensuring that every patient receives tailored treatment plans that address both their medical and emotional needs.

Our team of specialists collaborates closely with patients and their families, providing comprehensive support throughout the treatment journey. By fostering a compassionate environment and leveraging the latest technological innovations, we empower patients to navigate their recovery with confidence and optimism.

Conclusion

GoBroad Healthcare Group remains at the forefront of oncology research and treatment. Our recent achievement in Lu-177 nuclear therapy exemplifies our dedication to driving medical progress and expanding treatment possibilities for cancer patients. As a top oncology hospital, we continue to innovate, improve, and provide world-class oncology care. For those seeking advanced cancer treatment, GoBroad is the name to trust—a beacon of hope and medical excellence in the fight against cancer.